All In Biotech

Drug Trial Radar · NCT00736866

The Acetylcysteine for Contrast-Induced Nephropathy Trial

A Pragmatic Randomized Clinical Trial Evaluating the Effect of Acetylcysteine for Contrast-induced Nephropathy

Last checked: Nov 20, 2026Latest source record: Jul 12, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 2,300 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,300

Planned (sponsor's estimate)

Start

Aug 2008

Primary completion

Jul 2010

Study completion Jul 2010

Sponsor

Lead sponsor
Hospital do CoracaoAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Medley Pharmaceutical Industry SA
First posted
Aug 18, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy of acetylcysteine compared to placebo for the contrast-induced nephropathy prevention, between 48 and 96 hours after procedures that use contrast. Contrast-induced nephropathy is defined as an increase of 25% in serum creatinine before the procedure.

Conditions

  • Acute Kidney Failure

Interventions

  • AcetylcysteineDrug

    Acetylcysteine: 1200 mg every 12 hours for a total of 4 doses. Treatment is to be started 12 hours before angiography, that is, two doses should be administered before it. When this is not achievable, at least one dose should be administered before angiography.

  • PlaceboDrug

    Placebo of Acetylcysteine: every 12 hours PO, for a total of 4 doses. Treatment is to be started 12 hours before angiography, that is, two doses should be administered before it. When this is not achievable, at least one dose should be administered before angiography.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Contrast-induced nephropathy incidenceTime frame: between 48 and 96 hours after angiographic procedures

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hospital do Coração

    São Paulo, São Paulo, Brazil

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.